Trial Profile
Raloxifene-Alendronate Comparison in Postmenopausal Women with Low Bone Mass (EVA: Evista Alendronate Comparison)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Raloxifene (Primary) ; Alendronic acid
- Indications Fracture; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms EVA
- Sponsors Eli Lilly and Company
- 05 Nov 2010 New trial record.